C07D 213/40
Acylated substituent nitrogen atom
C07D213/40 (Acylated substituent nitrogen atom) appears on 1,190 US grants and 1,091 published applications in this corpus.
Search patents in C07D- Granted patents
- 1,190
- Published applications
- 1,091
- Assignees
- 607
- Inventors
- 4,132
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 12 | 0 |
| 1977 | 11 | 0 |
| 1978 | 16 | 0 |
| 1979 | 2 | 0 |
| 1980 | 5 | 0 |
| 1981 | 10 | 0 |
| 1982 | 12 | 0 |
| 1983 | 11 | 0 |
| 1984 | 7 | 0 |
| 1985 | 15 | 0 |
| 1986 | 8 | 0 |
| 1987 | 12 | 0 |
| 1988 | 16 | 0 |
| 1989 | 7 | 0 |
| 1990 | 16 | 0 |
| 1991 | 14 | 0 |
| 1992 | 13 | 0 |
| 1993 | 15 | 0 |
| 1994 | 20 | 0 |
| 1995 | 21 | 0 |
| 1996 | 48 | 0 |
| 1997 | 34 | 0 |
| 1998 | 43 | 0 |
| 1999 | 30 | 0 |
| 2000 | 25 | 0 |
| 2001 | 27 | 6 |
| 2002 | 32 | 41 |
| 2003 | 34 | 53 |
| 2004 | 29 | 75 |
| 2005 | 21 | 54 |
| 2006 | 33 | 50 |
| 2007 | 36 | 54 |
| 2008 | 23 | 58 |
| 2009 | 33 | 56 |
| 2010 | 36 | 44 |
| 2011 | 38 | 45 |
| 2012 | 31 | 34 |
| 2013 | 32 | 46 |
| 2014 | 38 | 64 |
| 2015 | 47 | 46 |
| 2016 | 47 | 50 |
| 2017 | 44 | 55 |
| 2018 | 29 | 44 |
| 2019 | 30 | 26 |
| 2020 | 29 | 44 |
| 2021 | 27 | 29 |
| 2022 | 24 | 31 |
| 2023 | 11 | 30 |
| 2024 | 15 | 26 |
| 2025 | 11 | 15 |
| 2026 | 10 | 15 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- NAMPT modulators29 Sep 2026US 12,747,203 B2Cytokinetics, Inc.
- Arylsulfonamides as orexin receptor agonists8 Sep 2026US 12,729,178 B2Research Triangle Institute
- Anti-inflammatory carboxamide derivatives21 Jul 2026US 12,686,657 B2Biomedcode Hellas SA
- Agents for differentiating stem cells and treating cancer19 May 2026US 12,630,512 B2Minerva Biotechnologies Corporation
- Inhibitors of YAP/TAZ-TEAD oncoproteins, synthesis and use thereof24 Mar 2026US 12,583,815 B2BridGene Biosciences, Inc.
- Bicyclic compounds8 Oct 2026US 2026/0308114 A1Vivace Therapeutics, Inc.
- Pyridine-piperazine-based scaffolds as highly potent and selective neurolysin activators1 Oct 2026US 2026/0294897 A1Board of Regents of the University of Nebraska
- Hdac1/2 selective inhibitor and use thereof1 Oct 2026US 2026/0297110 A1Wigen Biomedicine Technology (Shanghai) Co., Ltd.
- New compound and pharmaceutical composition comprising same27 Aug 2026US 2026/0250262 A1Samjin Pharmaceutical Co., Ltd.
- Visible light driven co2 valorization6 Aug 2026US 2026/0225999 A1The Board of Regents for the Oklahoma Agricultural and Mechanical Colleges
Most cited
By later US patents
- Arylsulfonylamino hydroxamic acid derivatives213US 5,863,949 APfizer Inc. · 1999
- Retroviral protease inhibiting compounds159US 5,142,056 AAbbott Laboratories · 1992
- Urea derivatives and their use as ACAT inhibitors134US 5,621,010 ANisshin Flour Milling Co., Ltd. · 1997
- Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method125US 5,760,246 A1998
- Cell differentiation inducer110US 6,174,905 B1Mitsui Chemicals, Inc. · 2001